IL326463A - Crystalline forms of a pi3k inhibitor and uses of same - Google Patents
Crystalline forms of a pi3k inhibitor and uses of sameInfo
- Publication number
- IL326463A IL326463A IL326463A IL32646326A IL326463A IL 326463 A IL326463 A IL 326463A IL 326463 A IL326463 A IL 326463A IL 32646326 A IL32646326 A IL 32646326A IL 326463 A IL326463 A IL 326463A
- Authority
- IL
- Israel
- Prior art keywords
- same
- crystalline forms
- pi3k inhibitor
- pi3k
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363532700P | 2023-08-15 | 2023-08-15 | |
| PCT/US2024/042221 WO2025038698A1 (en) | 2023-08-15 | 2024-08-14 | Crystalline forms of a pi3k inhibitor and uses of same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL326463A true IL326463A (en) | 2026-04-01 |
Family
ID=92632772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL326463A IL326463A (en) | 2023-08-15 | 2024-08-14 | Crystalline forms of a pi3k inhibitor and uses of same |
Country Status (7)
| Country | Link |
|---|---|
| AR (1) | AR133554A1 (en) |
| AU (1) | AU2024323620A1 (en) |
| CO (1) | CO2026001466A2 (en) |
| IL (1) | IL326463A (en) |
| MX (1) | MX2026001800A (en) |
| TW (1) | TW202509025A (en) |
| WO (1) | WO2025038698A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022265993A1 (en) | 2021-06-14 | 2022-12-22 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
| CN120529906A (en) * | 2022-10-31 | 2025-08-22 | 蝎子疗法股份有限公司 | Combination therapies for treating cancer |
-
2024
- 2024-08-14 IL IL326463A patent/IL326463A/en unknown
- 2024-08-14 WO PCT/US2024/042221 patent/WO2025038698A1/en active Pending
- 2024-08-14 TW TW113130461A patent/TW202509025A/en unknown
- 2024-08-14 AU AU2024323620A patent/AU2024323620A1/en active Pending
- 2024-08-15 AR ARP240102160A patent/AR133554A1/en unknown
-
2026
- 2026-02-09 CO CONC2026/0001466A patent/CO2026001466A2/en unknown
- 2026-02-13 MX MX2026001800A patent/MX2026001800A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202509025A (en) | 2025-03-01 |
| WO2025038698A9 (en) | 2025-06-05 |
| AR133554A1 (en) | 2025-10-08 |
| CO2026001466A2 (en) | 2026-03-05 |
| AU2024323620A1 (en) | 2026-02-19 |
| MX2026001800A (en) | 2026-03-02 |
| WO2025038698A1 (en) | 2025-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL326463A (en) | Crystalline forms of a pi3k inhibitor and uses of same | |
| IL310234A (en) | Salts and solid state forms of a kif18a inhibitor compound | |
| IL326350A (en) | Benzopyridinones and benzopyrimidinones as pi3k inhibitors | |
| IL326137A (en) | Pi3k inhibitors | |
| AU2024314618A1 (en) | Pi3k inhibitors and use thereof | |
| IL321053A (en) | Crystalline forms of a her2 inhibitor | |
| IL321357A (en) | Inhibitors of kif18a and uses thereof | |
| EP4244231A4 (en) | Crystalline solid meglumine salt inhibitor of bcl and methods of making and using same | |
| IL325861A (en) | Crystalline forms of a menin inhibitor | |
| CA3264917A1 (en) | Inhibitors of kif18a and uses thereof | |
| IL321007A (en) | Crystalline forms of a piperidine inhibitor of slc6a19 function | |
| EP4181921A4 (en) | Crystalline forms of a selective c-kit kinase inhibitor | |
| IL305791A (en) | Salt and solid forms of a kinase inhibitor | |
| IL319006A (en) | Crystalline forms of a pcsk9 inhibitor, compositions and uses | |
| HK40121198A (en) | Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof | |
| AU2021368138A9 (en) | Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof | |
| HUE073161T2 (en) | Crystalline form of jak inhibitor and application thereof | |
| HK40128961A (en) | Crystalline forms of a parp1 inhibitor | |
| HK40109581A (en) | Salts and solid state forms of a kif18a inhibitor compound | |
| CA3288716A1 (en) | Crystalline forms of a ras inhibitor | |
| HK40117256A (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| HK40086278A (en) | Crystalline forms of a tyk2 inhibitor | |
| HK40091715A (en) | Crystalline forms of a cd73 inhibitor and uses thereof | |
| IL326563A (en) | Crystalline forms of a bet inhibitor | |
| GB202101735D0 (en) | Solid forms of a plasma kallikrein inhibitor and salts thereof |